Browsing by Author "Geredeli, Caglayan"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study(FUTURE MEDICINE LTD, 2022-01-01) Yasin, Ayse Irem; Aydin, Sabin Goktas; Sumbul, Bilge; Koral, Lokman; Simsek, Melih; Geredeli, Caglayan; Ozturk, Akin; Perkin, Perihan; Demirtas, Derya; Erdemoglu, Engin; Hacibekiroglu, Ilhan; Cakir, Emre; Tanrikulu, Eda; Coban, Ezgi; Ozcelik, Melike; Celik, Sinemis; Teker, Fatih; Aksoy, Asude; Firat, Sedat T.; Tekin, Omer; Kalkan, Ziya; Turken, Orhan; Oven, Bala B.; Dane, Faysal; Bilici, Ahmet; Isikdogan, Abdurrahman; Seker, Mesut; Turk, Haci M.; Gumus, MahmutAim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2\% in the patient group and 97.5\% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2\% in the cancer patient group and 97.5\% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.Item Prognostic significance of primary tumor localization in stage II and III colon cancer(BAISHIDENG PUBLISHING GROUP INC, 2018-01-01) Sakin, Abdullah; Arici, Serdar; Secmeler, Saban; Can, Orcun; Geredeli, Caglayan; Yasar, Nurgul; Demir, Cumhur; Demir, Osman Gokhan; Cihan, SenerAIM To investigate the effects of tumor localization on disease free survival (DFS) and overall survival (OS) in patients with stage I -III colon cancer. METHODS This retrospective study included 942 patients with stage. and. colon cancer, which were followed up in our clinics between 1995 and 2017. The tumors from the caecum to splenic flexure were defined as right colon cancer (RCC) and those from splenic flexure to the sigmoid colon as left colon cancer (LCC). RESULTS The median age of the patients was 58 years (range: 19-94 years). Male patients constituted 54.2\%. The rates of RCC and LCC were 48.4\% (n = 456) and 51.6\% (n = 486), respectively. During the median follow-up of 90 mo (range: 6-252 mo), 14.6\% of patients developed recurrence and 9.1\% of patients died. In patients with stage. and. disease with or without adjuvant therapy, DFS was similar in terms of primary tumor localization (stage.